Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes

Abstract

Our proposed R grading system appears to be useful for predicting clinical outcomes after RFA.

Clinical usefulness of the ablative margin assessed by magnetic resonance imaging with Gd-EOB-DTPA for radiofrequency ablation of hepatocellular carcinoma

“…We compared EOB-MRI with enhanced CT with sufficient iodized oil deposition, which may be a gold standard of AM assessment [14,15]. Overall agreement between EOB-MRI and enhanced CT with sufficient iodized oil deposition was better that between EOB-MRI and enhanced CT, indicating EOB-MRI were more accurate than enhanced CT.…”

“…On EOB-MRI, 25% of nodules was indeterminate with 71% on unenhanced CT [16], 36% on unenhanced MRI [17], 10% on ferucarbotran-MRI [19], and 41% on enhanced CT with iodized oil deposition [15]. Furthermore, enhanced CT with iodized oil deposition can only apply to hypervascular HCCs.…”

“…The assessment of AM using the accumulation of iodized oil (lipiodol) within an HCC has been reported to enable evaluation of both the ablative area and the index tumor on identical images [13]. Therefore, enhanced CT with iodized oil deposition within an HCC may become the gold standard [14,15]. However, it requires arterial infusion of iodized oil and is invasive.…”

Radiofrequency Ablation for Hepatocellular Carcinoma Measuring 2 cm or Smaller: Results and Risk Factors for Local Recurrence

“…Furthermore, additional TACE before RFA has been reported to increase the volume of coagulation diameter [29]. In addition, the good therapeutic effect of TACE, the improved overall survival and the ease in recognizing SM by evaluating the accumulation of iodized oil on CECT help us to arrive at the correct assessment of treatment effect [30]. …”

Advances of diagnostic and mechanistic studies of γ-glutamyl transpeptidase in hepatocellular carcinoma

“…GGT was utilized as a diagnostic tumor biomarker for liver disease with a high sensitivity of 83-100%, but it only has a low specificity of 32% (10). Therefore, long since GGT was not utilized as an (29,(36)(37)(38)(39)(40). The combination of GGT and other indicators, such as tumor size, tumor number, MVI, or laboratory data for AFP and DCP, should be paid more attention when deciding a treatment and predicting the curative results for patients with HCC (41).…”